ROBERT NELSEN
CIK 1219042 · last filed 2026-06-08
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$488.74M
Companies
18
Total Filings
132
Lifetime Open-Market Net
$85.61M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PRME | Director | 6,128,297 | $3.00 | $18.42M | $43.60M | 8 | 2026-06-08 |
| SANA | Director | 12,447,375 | $3.23 | $40.14M | $10.00M | 15 | 2026-06-05 |
| LYEL | Director | 910,318 | $13.16 | $11.98M | $0 | 5 | 2024-06-17 |
| VIR | Director | 7,874,803 | $8.93 | $70.32M | $20.00M | 22 | 2024-06-03 |
| BOLD | 10%+ Owner | 1,048,433 | $2.52 | $2.64M | $12.80M | 1 | 2024-04-04 |
| NMRA | 10%+ Owner | 3,758,883 | $1.66 | $6.22M | $4.20M | 1 | 2023-09-27 |
| DNLI | Director | 9,681,181 | $24.48 | $237.00M | $0 | 8 | 2021-06-04 |
| Karuna Therapeutics, Inc. (KRTX) Delisted | Director | 1,461,704 | $329.83 | $482.11M | $3.20M | 6 | 2021-04-15 |
| BEAM | Director | 3,535,572 | $26.00 | $91.92M | $0 | 3 | 2021-04-02 |
| Unity Biotechnology, Inc. (UBX) Delisted | Director | 168,242 | $0.20 | $33.7K | $0 | 4 | 2020-06-22 |
| Sienna Biopharmaceuticals, Inc. (SNNA) Delisted | Director | 2,538,641 | — | — | $0 | 3 | 2018-06-05 |
| Juno Therapeutics, Inc. (JUNO) Delisted | Director | 3,234 | — | — | $0 | 13 | 2018-03-07 |
| Syros Pharmaceuticals, Inc. (SYRS) Delisted | Director | 463,714 | $0.00 | $185 | $5.00M | 4 | 2017-09-22 |
| AGIO | Director | 118,404 | $32.72 | $3.87M | -$20.75M | 10 | 2017-03-07 |
| Sage Therapeutics, Inc. (SAGE) Delisted | Director | 1,232,649 | $8.68 | $10.70M | $0 | 6 | 2015-11-12 |
| KYTHERA BIOPHARMACEUTICALS INC (KYTH) Delisted | Director | 957,604 | — | — | $0 | 8 | 2015-03-26 |
| Bellerophon Therapeutics, Inc. (BLPH) Delisted | Director | 50,200 | $0.01 | $602 | $2.55M | 1 | 2015-02-23 |
| FATE | Director | 2,473,188 | $2.52 | $6.22M | $5.00M | 1 | 2013-10-07 |
Recent Filings · Page 10 of 14
132 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2016-07-06 | Syros Pharmaceuticals, Inc. (SYRS) Delisted | Mixed | +4,423,804 | $5.00M | EDGAR |
| 2016-07-05 | Juno Therapeutics, Inc. (JUNO) Delisted | Grant (A) | +335 | $0 | EDGAR |
| 2016-06-23 | AGIO | Grant (A) | — | $0 | EDGAR |
| 2016-06-21 | Juno Therapeutics, Inc. (JUNO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-04-07 | Juno Therapeutics, Inc. (JUNO) Delisted | Grant (A) | +329 | $0 | EDGAR |
| 2015-11-12 | Sage Therapeutics, Inc. (SAGE) Delisted | Other (J) | −474,589 | $0 | EDGAR |
| 2015-09-29 | Sage Therapeutics, Inc. (SAGE) Delisted | Other (J) | −474,588 | $0 | EDGAR |
| 2015-06-25 | AGIO | Grant (A) | — | $0 | EDGAR |
| 2015-06-22 | Sage Therapeutics, Inc. (SAGE) Delisted | Other (J) | −1,008,353 | $0 | EDGAR |
| 2015-06-19 | AGIO | Other (J) | −732,904 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.